Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1995-03-02
1998-06-23
Schwadron, Ronald B.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 792, 435 793, 435 794, 435 795, 436501, 436536, 436811, 436817, 53038824, 53038825, 5303892, 5303893, 5303898, 5303889, G01N 3353, G01N 33536, G01N 3374, G01N 3700
Patent
active
057703760
ABSTRACT:
The present invention relates to methods for diagnosing acute myocardial infarction through the measurement of the level of marinobufagin-like immunoreactivity in the blood of patients suspected of this diagnosis; a method for treating patients with acute myocardial infarction with antibody to marinobufagin, a bufodienolide, to prevent the occurrence of cardiac arrhythmias; antibodies which specifically recognize marinobufagin or other bufodienolides; hybridomas producing these antibodies; a process for preparing such antibodies; and an immunoassay method for marinobufagin for research purposes using its specific antibody.
The antibodies of the present invention make it possible to conveniently measure bufodienolides with specificity and high sensitivity. This is useful in determining the existence and degree of hypertension and myocardial infarction, and in treating myocardial infarction.
REFERENCES:
patent: 5117834 (1992-06-01), Kroll et al.
patent: 5164296 (1992-11-01), Blaustein et al.
Anderson, D.E. & A.Bagrov, "Endogenous-Digoxin Like Factor (EDLF): Cardiovascular Responses to Volume Loading and pCO.sub.2 Regulation," J. Mol. Cell. Cardiol. 25(Suppl. I):S.22. Abstract II P 34 (1993).
Anderson, D.E. et al., "Inhibited Breathing Decreases Renal Sodium Excretion," Psychosom. Med. 57:373-380 (Jul.-Aug. 1995).
Bagrov, A.Y. et al., "Antiarrhythmic Effect of Antibodies to Digoxin in Acute Myocardial Ischemia in Rats," Eur. J. Pharmacol. 162:195-196 (1989).
Bagrov, A.Y. et al., "Antiarrhythmic Effect of Antibodies to Digoxin in Experimental Myocardial Infarction (the Arrhythmogenic Action of Endogenous Digoxinlike Factor)," pp. 919-921, translated from Bull. Exp. Biol Med. 112(7):20-21 (1991).
Bagrov, A. et al., "Digitalis-Like and Vasoconstrictor Properties of Endogenous Digoxin-Like Factor (EDLF) from Bufo Marinus Toad," J. Mol. Cell. Cardiol. 24(Suppl. I):S.259. Abstract P-08-30 (1992).
Bagrov, A.Y. et al., "Effect of Endogenous Digoxin Like Factor and Digoxin Antibody on Myocardial Na.sup.+, K.sup.+ -Pump Activity and Ventricular Arrhythmias in Acute Myocardial Ischaemia in Rats," Cardiovascular Res. 27:001-006 (1993).
Bagrov, A.Y. et al., "Effects of Two Endogenous Na.sup.+,K.sup.+ -ATPase Inhibitors, Marinobufagenin and Ouabain, on Isolated Rat Aorta," Eur. J. Pharmacol. 00:1-8 (1995).
Bagrov, A.Y. et al., "Endogenous Digitalis in Acute Myocardial Ischaemia/Infarction (AMI)," Biol. Chem. Hoppe-Seyler 374:610-611. Abstract SP-181 (1993).
Bagrov, A.Y. et al., "Endogenous Digoxin-Like Factor (EDLF) in Acute Myocardial Infarction (AMI)," J. Mol. Cell. Cardiol. 22(Suppl. III):S.29. Abstract PT4 (1990).
Bagrov, A. et al., "Endogenous Digoxin-Like Factor (EDLF): Pathophysiological Role in Acute Myocardial Ischaemia/Infarction (AMI)," J. Mol. Cell. Cardiol 25 (Suppl I):S.102. Abstract XI P 5 (1993).
Bagrov, A.Y. et al., "Endogenous Digoxin-Like Factor in Acute Myocardial Infarction," J. Intern. Med. 235(1):63-67 (1994).
Bagrov, A.Y., "Endogenous Digoxin-Like Factor: Possible Emergency Implications," Prehosp. Disaster Med. 5:186. Abstract (1990).
Bagrov, A.Y. et al., "Endogenous Marinobufagenin-Like Immunoreactive Factor and Na+, K+ ATPase Inhibition During Voluntary Hypoventilation," Hypertension 26(5):781-788. Abstract. (Nov. 1995).
Bagrov, A.Y. et al., "Endogenous Plasma Na,K-ATPase Inhibitory Activity and Digoxin Like Immunoreactivity After Acute Myocardial Infarction," Cardiovascul. Res. 25(5)371-377 (1991).
Bagrov, A. Y. et al., "Evidence for a Bufodienolide Na/K Pump Inhibitor in Human Urine," Am. J. Hypertension 9:133A-135A. Abstract D2 (1996).
Bagrov, A. Y. et al., "Marinobufagenin-Like Immunoreactive Substance, a Possible Endogenous Na,K-ATPase Inhibitor with Vasoconstrictor Activity," Am. J Hypertension 8(4):65A. Abstract C24 (Apr. 1995).
Bagrov, A. Y., et al., "Plasma Marinobufagenin-Like and Ouabain-Like Immunoreactivity During Saline Volume Expansion in Anesthetized Dogs," Cardiovascular Res. 31:296-305 (1996).
Blaustein, M.P., "The Cellular Basis of Cardiotonic Steroid Action," Trends Pharmacol. Sci. 6:289-292 (1985).
Bova, S. et al., "Effects of an Endogenous Ouabainlike Compound on Heart and Aorta," Hypertension 17(6):944-950 (1991).
Cloix, J.-F., "Endogenous Digitalislike Compounds: A Tentative Update of Chemical and Biological Studies," Hypertension 10(Suppl. 1):I-67-I-70 (1987).
Clough, D.L. et al., "Myocardial Na,K-ATPase Activity in Rats with Steroid and Spontaneous Hypertension," J. Hypertension 2(2):141-147 (1984).
De Mendonca, M. et al., "Hypotensive Action of Canrenone in a Model of Hypertension Where Ouabain-like Factors are Present," J. Hypertension 3 (Suppl. 3):S73-S78 (1985).
de Pover, A., "Endogenous Digitalis-Like Factor and Inotropic Receptor Sites in Rat Heart," Eur. J. Pharmacol. 99:365-366 (1984).
Delva, P. et al., "Correlations Between Plasma Levels of an Endogenous Digitalis-Like Substance and Haemodynamic Parameters Measured During Cardiac Catheterization," J. Hypertension 6(Suppl. 4):S-348 to S-350 (1988).
Doris, P.A. and D.M. Stocco, "An Endogenous Digitalis-Like Factor Derived from the Adrenal Gland: Studies of Adrenal Tissue from Various Sources," Endocrinology 125(5):2573-2579 (1989).
Fagoo, M. and T. Godfraind, "Interaction of Cardiodigin, Endogenous Inhibitor of Na.sup.+, K.sup.+ -ATPase, with Antidigoxin and Antidigitoxin Antibodies," Biochem. Biophys. Res. Commun. 129(2):553-559 (1985).
Fedorova, O.V. and A.Y. Bagrov, "Inhibition of Na/K ATPase from Rat Aorta by Two Endogenous Na-Pump Inhibitors, Ouabain and Marinobufagenin," Am. J. Hypertension 9(4):23A. Abstract (Apr. 1996).
Flier, J.S., "Ouabain-Like Activity in Toad Skin and Its Implications for Endogenous Regulation of Ion Transport," Nature 274:285-286 (1978).
Gonick, H.C. et al., "Circulating Inhibitor of Sodium-Potassium-Activated Adenosine Triphosphatase After Expansion of Extracellular Fluid Volume in Rats," Clin. Sci. Mol. Med. 53:329-334 (1977).
Goodlin, R.C., "Antidigoxin Antibodies in Eclampsia," N. Engl. J. Med. 318:518-519 (1988).
Graves, S.W., "The Possible Role of Digitalislike Factors in Pregnancy-Induced Hypertension," Hypertension 10(Suppl. I):I-84-I-86 (1987).
Hamlyn, J.M. et al., "A Circulating Inhibitor of (Na.sup.+ +K.sup.+)ATPase Associated with Essential Hypertension," Nature 300:650-652 (1982).
Harris, D. W. et al., "Development of an Immunoassay for Endogenous Digilitalislike Factor," Hypertension 17(6), Part 2:936-943 (1991).
Harris, W.J. and S. Emery, "Therapeutic Antibodies--the Coming of Age," Trends in Biotechnol. 11:42-44 (1993).
Harrison, T.R., "Specific Disorders of Rate and Rhythm," Harrison's Principles of Internal Medicine, Ninth Edition, Chapter 237, pp. 1051-1063, Isselbacher, K.J. et al., eds., McGraw-Hill Book Company, New York, 1980.
Huang, C.T. and R.M. Smith, "Lowering of Blood Pressure in Chronic Aortic Coarctate Hypertensive Rats with Anti-Digoxin Antiserum," Life Sci. 35:115-118 (1984).
Janse, M.J. and A.L. Wit, "Electrophysiological Mechanisms of Ventricular Arrhythmias Resulting From Myocardial Ischemia and Infarction," Am. Physiolog. Rev. 69(4):1049 & 1058-1061 (1989).
Kohn, R. et al., "Endogenous Digitalis-Like Factor in Patients with Acute Myocardial Infarction," Cor et Vasa. 34(3):227-237. Abstract. (1992).
Kojima et al., "Involvement of Endogenous Digitilas-Like Substance in Genesis of Deoxycorticosterone-Salt Hypertension," Life Sci. 30:1775-1781 (1982).
Kunes, J. et al., "The Importance of Endogenous Digoxin-Like Factors in Rats with Various Forms of Experimental Hypertension," Clin. and Exper.--Theory and Practice A7(5&6):707-720 (1985).
Lichtstein, D. et al, "Demonstration of a Ouabainlike Plasma Compound in Hypertension Prone and Hypertension Resistant Rats," Hypertension 7(5):729-733 (1985).
Ludens, J.H. et al., "Purification of an Endogenous Digitalislike Factor From Human Plasma for Structural Analysis," Hypertension 17(6), Part 2:923-929 (1991).
Mir, M.A. et al., "Problems and Pitfalls in the Isolation of an Endogenous Na.sup.+,K.sup.+ -ATPase Inhibitor," Hypertension 10(5)(Suppl. 1):I-57-I60 (1987).
Schoner, W., "Endo
Biomedical Sciences Research Laboratories, Inc.
Schwadron Ronald B.
LandOfFree
Method of diagnosing and treating myocardial infarction and hype does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of diagnosing and treating myocardial infarction and hype, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing and treating myocardial infarction and hype will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1393409